Lidolog Kit, 2% recall — Asclemed Usa Inc. (Class III)

Asclemed Usa Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Lidolog Kit, 2% — a Class III recall, initiated 2026-07-15 and posted to the FDA enforcement report on 2026-07-29, under recall number D-0713-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan”. From the product description, the form is injection, the strengths given are 2% and 2mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 76420-760-01. Distribution is recorded as “Within U.S. - Tennessee”, with the recalling firm on record in CA, United States. It is the only recall number the FDA has filed under event ID 99408. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0713-2026
FDA event ID 99408
Classification Class III (least serious regulatory tier)
Status Ongoing
Recalling firm Asclemed Usa Inc.
Recall initiated 2026-07-15
Reported by FDA 2026-07-29
Report lag 14 days from initiation to report
Distribution Within U.S. - Tennessee
Firm location on record CA, United States
Product description (source) Lidolog Kit, Kit Contains: Lidocaine HCl Injection, USP, 2% (2mL) vial, 1 Dose, Single use Only, Rx Only, Distributed by: Enovachem Pharmaceuticals, Torrance, CA 90501, NDC: 76420-760-01.

Reason reported by FDA

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

15 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 27-word product description above; each is a literal substring of it.

Product named Lidolog Kit
Form Injection · Kit
Strength 2% · 2mL
NDC 76420-760-01
Marketing category Rx only
Distributed by Enovachem Pharmaceuticals, Torrance

Other indexed recalls from Asclemed Usa Inc.

4 indexed records name Asclemed Usa Inc. as the recalling firm, across 3 FDA events, reported 2026-06-10 to 2026-07-29. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Accucaine, 1%D-0658-2026Class II1% · Injection2026-07-08
Lidocaine HCl Injection USP, 1%D-0659-2026Class II1% · Injection2026-07-08
Duloxetine DR Capsules, 30 mgD-0555-2026Class II30 mg · Capsules2026-06-10

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 4 are the Class III ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Dabigatran etexilate Capsules, 110 mgD-0735-2026Ascend Laboratories, LLCClass III2026-07-29
Dabigatran etexilate Capsules, 150 mgD-0736-2026Ascend Laboratories, LLCClass III2026-07-29
Fexofenadine Hydrochloride Tablets, 180 mgD-0654-2026Sun Pharmaceutical Industries IncClass III2026-07-08
hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mLD-0619-2026Ani Pharmaceuticals, Inc.Class III2026-07-01

Nearest Class III recalls by date

25 of 250 indexed records share the Class III tier; the 9 nearest to 2026-07-29 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Dabigatran Etexilate Capsules, 150 mgD-0737-2026Ascend Laboratories, LLC150 mg · Capsules2026-08-05
Dabigatran Etexilate Capsules, 75 mgD-0738-2026Ascend Laboratories, LLC75 mg · Capsules2026-08-05
Dabigatran Etexilate Capsules, 75 mgD-0739-2026Ascend Laboratories, LLC75 mg · Capsules2026-08-05
Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 416.8 mLD-0740-2026Central Admixture Pharmacy Services Inc416.8 mL · Injection2026-08-12
Focalin XR (dexmethylphenidate HCl) 5 mgD-0608-2026Sandoz Inc5 mg · Extended-Release Capsules2026-06-24
Epinephrine Injection, 1mg/mLD-0581-2026Fresenius Kabi Usa, LLC1mg/mL · Injection2026-06-17
Primidone Tablets, 50 mgD-0585-2026Amneal Pharmaceuticals, LLC50 mg · Tablets2026-06-17
Lidocaine HCl Injection, 2%D-0552-2026Eugia US LLC2% · Injection2026-06-10
Nicotine Transdermal System Patch, 14 mgD-0550-2026Aveva Drug Delivery Systems, Inc.14 mg · Transdermal System2026-06-03

Reading this record

Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 76420-760-01 at the FDA source to confirm it is covered.

Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Asclemed Usa Inc. (4 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0713-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0713-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-29
Ingested
2026-08-22
Record hash
64ddb5918a31b1ea

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.